Advancements in developing an effective and preventive dengue vaccine

Every year millions of people in various tropical and subtropical regions encounter infection with dengue virus. Within the last few decades, its prevalence has increased up to 30-fold globally and presently these viruses have been transmitted in more than 100 countries. Scientists contributed to the development of tetravalent dengue vaccine by adopting numerous approaches including live vaccine, recombinant protein vaccine, DNA vaccine and virus-vectored vaccines. A vaccine should be genetically stable, equally effective against all serotypes, must be in-expensive and commercially available. Chimeric yellow fever virus-tetravalent dengue vaccine (CYD-TDV) is the first licensed vaccine developed by Sanofi Pasteur in December 2015, but this vaccine is not fully effective against different dengue virus serotypes (Sanofi Pasteur, Lyon, France). This review explores the advancements and challenges involved in the development of dengue vaccine.

Download Full-text

Dengue Vaccine Development at the Dengue virus serotypes

International Islamic Medical Journal ◽

10.33086/iimj.v1i1.1360 ◽

2019 ◽

Vol 1 (1) ◽

pp. 9-15

Author(s):

Adinda Desi Irawati ◽

Hotimah Masdan Salim

Keyword(s):

Dengue Virus ◽

Vaccine Development ◽

Hemorrhagic Fever ◽

Severe Dengue ◽

Vaccine Recombinant ◽

Dengue Vaccine ◽

Live Attenuated Vaccine ◽

Virus Particles ◽

Dengue Virus Serotypes ◽

Official Data

Dengue hemorrhagic fever (DHF) is a disease caused by dengue virus (DENV1-4) and is transmitted by the Aedes aegypti mosquito. However, in 2015, official data from the member countries, WHO reported more than 3.2 million cases, including 10,200 severe dengue cases and 1181 deaths. The protein encoded by the genome of dengue virus. Major structural and non structural proteins making up the genome of dengue. From genomic data several studies found that mechanism of vaccine that can use in dengue virus. Several vaccines was establish in the world for example Live attenuated Vaccine, Chimera Vaccine, Subunit Vaccine, DNA vaccines DENV, Activated DENV Vaccine - Whole Virus Particles, Activated DENV Vaccine - Recombinant Subunit DENV, and DENV Vaccine 5.

Download Full-text

Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

10.1101/645457 ◽

2019 ◽

Author(s):

Web Smith ◽

John Smith

Keyword(s):

Nucleic Acid ◽

Recombinant Protein ◽

Vaccine Group ◽

Protein Vaccine ◽

Vaccine Recombinant ◽

Nucleic Acid Vaccine ◽

Immunization Group ◽

Recombinant Protein Vaccine ◽

Group B

AbstractThis report demonstrates a novel method to explore and evaluate the specific humoral/cellular immune response levels and immunoprotective effects of NMB0315 nucleic acid vaccine, recombinant protein vaccine and nucleic acid vaccine + recombinant protein vaccine in combination with mice, and to further explore the effective immunization method for NMB0315 vaccine. This route provides experimental basis. Nucleic acid vaccines [pcDNA3 1(+) / NMB0315] and recombinant protein vaccines (pET 30a / NMB0315) were prepared in large quantities, and immunologically or separately immunized female BALB/c mice were determined by nucleic acid priming protein boosting method. The specific humoral/cell immune response level, the in vitro bactericidal titer of immune serum, and the immunoprotective effect of the vaccine on mice infected with group B meningococcus were observed. Serum-specific IgG, IgG1, IgG2a and genital lavage fluids induced by NMB0315 nucleic acid vaccine group (pNMB0315 CpG), protein vaccine group (rNMB0315 FA) and combined immunization group (pNMB0315 CpG+rNMB0315 FA). The specific sIgA level reached the peak in the eighth week, and the A450 values were in vitro, and the in vitro bactericidal antibody titers of the nucleic acid vaccine group, the protein vaccine group and the combined immunization group were 1, 64, 1128, respectively. The immune protection rate of experimental mice were 70%, 95% and 80%, respectively. At 2, 4, 6, and 8 weeks, the ratio of IgG2a / IgG1 in the nucleic acid vaccine group, the recombinant protein vaccine group, and the combined immunization vaccine group was less than 1.

Download Full-text

Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B

FEMS Immunology & Medical Microbiology ◽

10.1111/j.1574-695x.2010.00763.x ◽

2011 ◽

Vol 61 (2) ◽

pp. 197-204 ◽

Cited By ~ 23

Author(s):

Jason R. Clark ◽

Kathryn Bartley ◽

Catherine D. Jepson ◽

Vicki Craik ◽

John B. March

Keyword(s):

Hepatitis B ◽

Recombinant Protein ◽

Dna Vaccine ◽

Protein Vaccine ◽

Recombinant Protein Vaccine

Download Full-text

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A

Vaccine ◽

10.1016/j.vaccine.2004.01.031 ◽

2004 ◽

Vol 22 (13-14) ◽

pp. 1592-1603 ◽

Cited By ~ 63

Author(s):

Judith E Epstein ◽

Yupin Charoenvit ◽

Kent E Kester ◽

Ruobing Wang ◽

Rhonda Newcomer ◽

...

Keyword(s):

Recombinant Protein ◽

Dna Vaccine ◽

Antibody Responses ◽

Protein Vaccine ◽

Recombinant Protein Vaccine

Download Full-text

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1

Vaccine ◽

10.1016/s0264-410x(99)00522-8 ◽

2000 ◽

Vol 18 (17) ◽

pp. 1793-1801 ◽

Cited By ~ 31

Author(s):

D.T O’Hagan ◽

M Ugozzoli ◽

J Barackman ◽

M Singh ◽

J Kazzaz ◽

...

Keyword(s):

Recombinant Protein ◽

Protein Vaccine ◽

Recombinant Protein Vaccine ◽

Hiv 1

Download Full-text

A DNA Vaccine against Yellow Fever Virus: Development and Evaluation

PLoS Neglected Tropical Diseases ◽

10.1371/journal.pntd.0003693 ◽

2015 ◽

Vol 9 (4) ◽

pp. e0003693 ◽

Cited By ~ 22

Author(s):

Milton Maciel ◽

Fábia da Silva Pereira Cruz ◽

Marli Tenório Cordeiro ◽

Márcia Archer da Motta ◽

Klécia Marília Soares de Melo Cassemiro ◽

...

Keyword(s):

Dna Vaccine ◽

Yellow Fever ◽

Yellow Fever Virus ◽

Fever Virus

Download Full-text

Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes

Clinical and Vaccine Immunology ◽

10.1128/cvi.00330-06 ◽

2006 ◽

Vol 14 (2) ◽

pp. 182-189 ◽

Cited By ~ 32

Author(s):

David H. Holman ◽

Danher Wang ◽

Kanakatte Raviprakash ◽

Nicholas U. Raja ◽

Min Luo ◽

...

Keyword(s):

Immune Responses ◽

Dengue Virus ◽

Vaccine Development ◽

De Novo ◽

Natural Infection ◽

Hemorrhagic Fever ◽

Virus Infections ◽

Dengue Vaccine ◽

Membrane Antigens ◽

Dengue Virus Serotypes

ABSTRACT Dengue virus infections can cause hemorrhagic fever, shock, encephalitis, and even death. Worldwide, approximately 2.5 billion people live in dengue-infested regions with about 100 million new cases each year, although many of these infections are believed to be silent. There are four antigenically distinct serotypes of dengue virus; thus, immunity from one serotype will not cross-protect from infection with the other three. The difficulties that hamper vaccine development include requirements of the natural conformation of the envelope glycoprotein to induce neutralizing immune responses and the necessity of presenting antigens of all four serotypes. Currently, the only way to meet these requirements is to use a mixture of four serotypes of live attenuated dengue viruses, but safety remains a major problem. In this study, we have developed the basis for a tetravalent dengue vaccine using a novel complex adenovirus platform that is capable of expressing multiple antigens de novo. This dengue vaccine is constructed as a pair of vectors that each expresses the premembrane and envelope genes of two different dengue virus serotypes. Upon vaccination, the vaccine expressed high levels of the dengue virus antigens in cells to mimic a natural infection and induced both humoral and cellular immune responses against multiple serotypes of dengue virus in an animal model. Further analyses show the humoral responses were indeed neutralizing against all four serotypes. Our studies demonstrate the concept of mimicking infections to induce immune responses by synthesizing dengue virus membrane antigens de novo and the feasibility of developing an effective tetravalent dengue vaccine by vector-mediated expression of glycoproteins of the four serotypes.

Download Full-text